Ark Therapeutics has been selected to manufacture and supply Lymfactin to Laurantis Pharma under a conditional agreement announced today by the Finland-based companies. The agreement is subject to Laurantis receiving regulatory approval to commence its Phase I trial. Terms of the agreement were not disclosed. Lymfactin uses an adenoviral vector to deliver vascular endothelial growth factor (VEGF-C) during transplantation of lymph nodes in order to avoid lymphedema. Ark is a CDMO focused on vira...